| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 500mg | |||
| 1g | |||
| Other Sizes |
| ln Vivo |
In first-trimester (11–14 weeks of gestation) pregnant women, serum levels of Stearoylcarnitine were significantly lower in those who later developed preeclampsia compared to women with normal pregnancies [1]
As a potential metabolic marker for preeclampsia prediction, Stearoylcarnitine exhibited certain diagnostic performance, with a measurable area under the receiver operating characteristic curve (AUC) when used alone for preeclampsia screening [1] |
|---|---|
| References | |
| Additional Infomation |
O-Octadecanoyl L-carnitine is an O-acyl L-carnitine, where the acyl group is specifically defined as a stearoyl (octadecanoyl). It is a human metabolite. It is a saturated fatty acyl L-carnitine and also a long-chain fatty acyl L-carnitine. Functionally, it is related to octadecanoic acid.
Stearylcarnitine is a long-chain acylcarnitine involved in fatty acid metabolism[1] Reference [1] used metabolomics methods to focus on the level of stearoylcarnitine in serum during early pregnancy in order to find its potential as a predictive biomarker for preeclampsia[1] The experimental procedure included: collecting serum samples from pregnant women at 11-14 weeks of gestation, pre-processing the samples (e.g., protein precipitation, derivatization), detecting the concentration of stearoylcarnitine using liquid chromatography-mass spectrometry (LC-MS), statistically comparing the stearoylcarnitine levels in the preeclampsia group and the normal control group, and evaluating its predictive efficacy[1] This study did not explore the pharmacological activity, molecular target, toxicity, or pharmacokinetics of stearoylcarnitine[1] |
| Molecular Formula |
C25H49NO4
|
|---|---|
| Molecular Weight |
427.660868406296
|
| Exact Mass |
427.366
|
| CAS # |
25597-09-5
|
| PubChem CID |
52922056
|
| Appearance |
White to off-white solid powder
|
| LogP |
8.8
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
21
|
| Heavy Atom Count |
30
|
| Complexity |
426
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O(C(CCCCCCCCCCCCCCCCC)=O)[C@H](CC(=O)[O-])C[N+](C)(C)C
|
| InChi Key |
FNPHNLNTJNMAEE-HSZRJFAPSA-N
|
| InChi Code |
InChI=1S/C25H49NO4/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-25(29)30-23(21-24(27)28)22-26(2,3)4/h23H,5-22H2,1-4H3/t23-/m1/s1
|
| Chemical Name |
(3R)-3-octadecanoyloxy-4-(trimethylazaniumyl)butanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~7.14 mg/mL (~16.70 mM)
H2O : < 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.85 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.85 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.85 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 50 mg/mL (116.92 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3383 mL | 11.6915 mL | 23.3831 mL | |
| 5 mM | 0.4677 mL | 2.3383 mL | 4.6766 mL | |
| 10 mM | 0.2338 mL | 1.1692 mL | 2.3383 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
